Abilify Maintena - Beechwood Capital

Drug Profile

ModalitySmall molecule

RouteIM

Therapy AreaNeurology

Launch2013-02-28

US LOE2025-10-01

Peak Sales Est$500M

Formulations[{"id":"maintena-im","route":"IM","device":"Lyophilized powder for reconstitution (300mg, 400mg)","s

Companies

4578 (ORIGINATOR)80%

LUN (CO_DEVELOPER)20%

Expert: Partial agonist at dopamine D2/D3 and serotonin 5-HT1A receptors with antagonism at 5-HT2A receptors. Stabilizes dopaminergic and serotonergic neurotransmission by acting as a functional agonist in hypodopaminergic states and antagonist in hyperdopaminergic states.

Everyday: Fine-tunes dopamine and serotonin signals in the brain — like a thermostat that adjusts these chemical messengers up or down depending on what the brain needs, rather than simply turning them on or off.

Targets: []

Period	Revenue ($M)
2024	$1,500M
2025	$1,200M

Indication	Stage	Key Study	Regional Status
Schizophrenia	APPROVED	Phase 3	[{"stage":"APPROVED","region":"US","approval_date":"2013-02-28"},{"stage":"APPRO
Bipolar I maintenance	APPROVED	Phase 3	[{"stage":"APPROVED","region":"US","approval_date":"2017-03-01"}]